GO:0042532 negative regulation of tyrosine phosphorylation of STAT protein: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0042532 describes any process that stops, prevents, or reduces the phosphorylation of tyrosine residues on STAT proteins, thereby limiting STAT activation.
• The JAK-STAT pathway is the primary route for cytokine-driven STAT tyrosine phosphorylation, and its negative regulation is essential to prevent excessive or prolonged signaling.
• Key negative regulators include SOCS proteins, protein tyrosine phosphatases such as SHP-1, and intramolecular inhibitory mechanisms within JAK kinases.
• Dysregulation of this process contributes to cancer, inflammatory diseases, and immune pathology, making it a therapeutic target.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of negative regulators in this pathway.
• Understanding GO:0042532 helps researchers interpret cytokine signaling, immune regulation, and oncogenesis.
Description
The JAK-STAT pathway is a central signaling cascade that transmits extracellular cytokine and growth factor signals to the nucleus, controlling gene expression programs involved in immunity, proliferation, differentiation, and survival. A critical step in this pathway is the phosphorylation of STAT proteins on specific tyrosine residues, which triggers STAT dimerization, nuclear translocation, and DNA binding. The Gene Ontology term GO:0042532, negative regulation of tyrosine phosphorylation of STAT protein, captures the cellular processes that restrain this activation step. This regulation is essential for maintaining signaling homeostasis and preventing pathological overactivation.
negative regulation of tyrosine phosphorylation of STAT protein At A Glance
| GO ID | GO:0042532 |
|---|---|
| GO term | negative regulation of tyrosine phosphorylation of STAT protein |
| Ontology | biological_process |
| Synonym | down regulation of tyrosine phosphorylation of STAT protein; inhibition of tyrosine phosphorylation of STAT protein; negative regulation of tyrosine phosphorylation of Stat1 protein; negative regulation of tyrosine phosphorylation of Stat3 protein; negative regulation of tyrosine phosphorylation of Stat5 protein |
| Major function | Restricts STAT activation by preventing or reducing tyrosine phosphorylation, thereby modulating cytokine and growth factor signaling. |
| Related pathways | JAK-STAT signaling, cytokine signaling, immune regulation. |
| Key negative regulators | SOCS proteins, SHP-1, PTPs, intramolecular JAK inhibitory domains. |
| Disease relevance | Cancer, inflammation, autoimmune diseases, glioma. |
What Is GO:0042532?
GO:0042532 is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of the introduction of a phosphate group to a tyrosine residue of a STAT (Signal Transducer and Activator of Transcription) protein. In other words, it encompasses all molecular mechanisms that negatively control the tyrosine phosphorylation of STAT family members (STAT1, STAT2, STAT3, STAT4, STAT5, STAT6, and STAT7 where applicable), thereby limiting their activation.
Why Is negative regulation of tyrosine phosphorylation of STAT protein Important in Cell Biology?
Negative regulation of STAT tyrosine phosphorylation is crucial for preventing excessive or prolonged cytokine signaling, which can lead to chronic inflammation, autoimmunity, and cancer. This process ensures that immune responses are appropriately resolved and that cell growth signals are tightly controlled. Understanding its mechanisms provides insights into disease pathogenesis and identifies potential targets for therapeutic intervention.
• Prevents sustained STAT activation that could drive oncogenesis.
• Limits inflammatory responses by attenuating cytokine signaling.
• Maintains immune homeostasis and prevents autoimmunity.
• Regulates hematopoiesis and immune cell development.
• Influences cancer cell proliferation and survival, especially in gliomas.
• Provides targets for therapeutic modulation of JAK-STAT signaling.
• Key for understanding cytokine resistance in tumors.
• Essential for interpreting CRISPR screens targeting signaling regulators.
• Helps explain off-target effects of JAK inhibitors.
• Guides development of precision medicines for immune disorders.
What Happens During negative regulation of tyrosine phosphorylation of STAT protein?
SOCS-mediated inhibition
In simple terms: SOCS proteins act like brakes on the JAK-STAT pathway.
Suppressor of cytokine signaling (SOCS) proteins are induced by STAT activation and feedback to inhibit JAK kinase activity, thereby reducing STAT tyrosine phosphorylation. SOCS1 and SOCS3 bind to JAKs or cytokine receptors, blocking their catalytic activity and promoting degradation. This feedback loop is a primary mechanism for negative regulation of STAT phosphorylation.
Phosphatase-mediated dephosphorylation
In simple terms: Phosphatases remove phosphate groups from STATs, turning them off.
Protein tyrosine phosphatases such as SHP-1 (PTPN6) directly dephosphorylate JAKs and STATs, terminating signaling. SHP-1 is a critical negative regulator of IL-4 and IL-13 signaling, reducing STAT6 phosphorylation. Other PTPs, including PTP1B and TC-PTP, also contribute to STAT dephosphorylation.
Intramolecular JAK inhibition
In simple terms: JAK kinases can self-inhibit through internal structural interactions.
A novel intramolecular negative regulation of mouse Jak3 activity by tyrosine 820 has been described, where phosphorylation of Y820 within the kinase domain reduces JAK3 activity and downstream STAT phosphorylation. This represents a self-limiting mechanism intrinsic to JAK kinases.
ARAP2 and SOCS1 restriction
In simple terms: ARAP2 helps control interferon-gamma responses by limiting SOCS1.
ARAP2 regulates responses to interferon-gamma by restricting SOCS1, thereby modulating STAT1 phosphorylation. This illustrates how accessory proteins can fine-tune negative regulation of STAT tyrosine phosphorylation.
Key Genes Involved in GO:0042532 negative regulation of tyrosine phosphorylation of STAT protein
The following genes and proteins are central to the negative regulation of STAT tyrosine phosphorylation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SOCS1 | Inhibits JAK kinase activity, reducing STAT phosphorylation | Frequently studied in cytokine signaling and cancer |
| SOCS3 | Binds to JAK and cytokine receptors to block STAT activation | Key regulator of inflammation and metabolism |
| PTPN6 (SHP-1) | Dephosphorylates JAKs and STATs, terminating signaling | Critical for immune regulation and hematopoiesis |
| PTPN1 (PTP1B) | Dephosphorylates JAK2 and STATs | Metabolic and oncogenic signaling |
| PTPN2 (TC-PTP) | Negative regulator of JAK-STAT signaling | Inflammation and cancer |
| JAK3 | Intramolecular inhibition via Y820 | Target for immunosuppression |
| ARAP2 | Restricts SOCS1 to modulate IFN-gamma responses | Interferon signaling and immune regulation |
| CISH | Cytokine-inducible SH2-containing protein, inhibits STAT5 | Negative feedback in cytokine signaling |
| PIAS | Protein inhibitor of activated STAT, blocks STAT DNA binding | Transcriptional regulation |
| STAT1 | Target of negative regulation | Interferon signaling |
| STAT3 | Target of negative regulation | Oncogenesis and inflammation |
| STAT5 | Target of negative regulation | Hematopoiesis and leukemia |
| STAT6 | Target of negative regulation | Allergic inflammation |
| JAK1 | Kinase upstream of STATs, regulated by SOCS | Cytokine signaling |
| JAK2 | Kinase upstream of STATs, regulated by SOCS and PTPs | Myeloproliferative neoplasms |
| TYK2 | Kinase upstream of STATs | Immune signaling |
How Is negative regulation of tyrosine phosphorylation of STAT protein Regulated?
The process of negative regulation of STAT tyrosine phosphorylation is itself tightly regulated. SOCS proteins are transcriptionally induced by STAT activation, creating a negative feedback loop. Their stability and activity are modulated by additional factors such as ARAP2, which restricts SOCS1 to control interferon-gamma responses. Phosphatases like SHP-1 are constitutively expressed but can be regulated by recruitment to receptor complexes. Intramolecular inhibitory phosphorylation of JAK3 at Y820 provides a rapid self-limiting mechanism. Together, these layers ensure balanced signaling.
negative regulation of tyrosine phosphorylation of STAT protein and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SOCS1 | Autoimmunity, cancer | Knockout mice, CRISPR KO cell lines |
| PTPN6 (SHP-1) | Autoimmune diseases, leukemia | Point mutation knock-in models |
| JAK3 | Immunodeficiency, leukemia | Y820F knock-in to disrupt intramolecular inhibition |
| ARAP2 | Interferonopathies | Overexpression and KO models |
| STAT3 | Glioma, inflammatory diseases | Conditional KO, point mutation |
Cancer
Dysregulation of negative regulation of STAT tyrosine phosphorylation leads to constitutive STAT activation, which is a hallmark of many cancers, including gliomas. Loss of SOCS proteins or phosphatases can drive oncogenesis by sustaining proliferative and survival signals. Therapeutic targeting of oncogenic tyrosine phosphatases is an emerging strategy.
Inflammatory and autoimmune diseases
Impaired negative regulation results in excessive cytokine signaling and chronic inflammation. SHP-1 deficiency causes severe autoimmune and inflammatory phenotypes. SOCS1 mutations are linked to autoimmunity.
Immune deficiencies
ARAP2 mutations affecting SOCS1 restriction can alter interferon-gamma responses, potentially leading to immune dysregulation. Intramolecular JAK3 inhibition defects may contribute to immunodeficiency or autoimmunity.
From negative regulation of tyrosine phosphorylation of STAT protein-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SOCS1 increase STAT phosphorylation? | SOCS1 knockout cell line |
| Does SHP-1 phosphatase activity require catalytic cysteine? | SHP-1 point mutation (C453S) knock-in |
| Does JAK3 Y820 phosphorylation inhibit STAT activation? | JAK3 Y820F knock-in |
| Does ARAP2 restrict SOCS1 to modulate IFN-gamma signaling? | ARAP2 overexpression and knockout |
| Can STAT3 tyrosine phosphorylation be monitored in real time? | STAT3 tagged knock-in (e.g., GFP) |
| What is the role of SOCS3 in inflammation? | SOCS3 conditional knockout |
How to Study the negative regulation of tyrosine phosphorylation of STAT protein Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Western blot | Phospho-STAT levels | Validation of negative regulators |
| CRISPR screen | Genes affecting STAT phosphorylation | Discovery of novel regulators |
| Phosphoproteomics | Global tyrosine phosphorylation | Pathway mapping |
| Immunoprecipitation | Protein-protein interactions | SOCS-JAK binding |
| Luciferase reporter | STAT transcriptional activity | Functional readout |
| Flow cytometry | Phospho-STAT in single cells | Immune cell signaling |
| Live-cell imaging | STAT nuclear translocation | Dynamics of regulation |
Phospho-STAT immunoblotting
Western blotting with phospho-specific antibodies against STAT tyrosine residues is the standard method to assess negative regulation. It measures the balance between kinase and phosphatase activities.
CRISPR screening
Genome-wide CRISPR knockout screens can identify negative regulators of STAT phosphorylation by using phospho-STAT readouts. This approach has uncovered SOCS proteins and phosphatases.
Proteomics and phosphoproteomics
Mass spectrometry-based phosphoproteomics enables global mapping of STAT tyrosine phosphorylation sites and quantification of changes upon perturbation.
Live-cell imaging
Fluorescently tagged STAT knock-in cells allow real-time visualization of STAT nuclear translocation as a downstream readout of tyrosine phosphorylation.
How CRISPR Can Be Used to Study GO:0042532 negative regulation of tyrosine phosphorylation of STAT protein
Knockout
CRISPR knockout of negative regulators such as SOCS1 or PTPN6 leads to enhanced STAT tyrosine phosphorylation, providing causal evidence for their role. Knockout cell lines are valuable for studying pathway hyperactivation.
Point Mutation
Point mutations can abrogate catalytic activity or phospho-acceptor sites. For example, a JAK3 Y820F knock-in prevents intramolecular inhibition, increasing STAT phosphorylation. SHP-1 catalytic dead mutants (C453S) are used to study phosphatase function.
Knock-in
Knock-in of tagged STAT proteins (e.g., GFP-STAT1) allows real-time monitoring of phosphorylation and localization. Knock-in of reporter genes under STAT-responsive promoters enables transcriptional readouts.
Overexpression
Overexpression of SOCS proteins or phosphatases suppresses STAT phosphorylation, confirming their negative regulatory roles. Inducible overexpression systems allow temporal control.
How EDITGENE Supports negative regulation of tyrosine phosphorylation of STAT protein Research
Researchers studying negative regulation of tyrosine phosphorylation of STAT protein-related genes often need to determine whether a candidate gene is causally involved in modulating STAT activation. EDITGENE provides comprehensive CRISPR services to enable such investigations.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of tyrosine phosphorylation of STAT protein research.
Frequently Asked Questions About negative regulation of tyrosine phosphorylation of STAT protein
What is GO:0042532?
GO:0042532 is the Gene Ontology term for negative regulation of tyrosine phosphorylation of STAT protein, describing processes that reduce STAT tyrosine phosphorylation.
What genes are involved in negative regulation of STAT tyrosine phosphorylation?
Key genes include SOCS1, SOCS3, PTPN6 (SHP-1), PTPN1, PTPN2, JAK3, ARAP2, and CISH.
How does SOCS1 inhibit STAT phosphorylation?
SOCS1 binds to JAK kinases and inhibits their catalytic activity, thereby reducing STAT tyrosine phosphorylation.
What is the role of SHP-1 in STAT regulation?
SHP-1 is a protein tyrosine phosphatase that dephosphorylates JAKs and STATs, acting as a negative regulator of IL-4 and IL-13 signaling.
Can CRISPR be used to study negative regulation of STAT phosphorylation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect this process.
What diseases are associated with defective negative regulation of STAT phosphorylation?
Cancer, autoimmune diseases, inflammatory disorders, and immunodeficiencies.
How is STAT tyrosine phosphorylation measured?
Common methods include phospho-specific Western blotting, flow cytometry, and phosphoproteomics.
What is the role of JAK3 Y820 in STAT regulation?
Phosphorylation of JAK3 at Y820 provides intramolecular negative regulation, reducing JAK3 activity and downstream STAT phosphorylation.
How does ARAP2 regulate STAT phosphorylation?
ARAP2 restricts SOCS1 to modulate interferon-gamma responses, thereby influencing STAT1 phosphorylation.
Why is negative regulation of STAT phosphorylation important in cancer?
Loss of negative regulation leads to constitutive STAT activation, driving proliferation and survival in cancers such as glioma.
Conclusion
GO:0042532 encompasses essential mechanisms that restrain STAT tyrosine phosphorylation, protecting against excessive cytokine signaling and disease. Key regulators such as SOCS proteins, phosphatases, and intramolecular JAK inhibition are critical for immune homeostasis and cancer prevention. CRISPR-based models offer powerful approaches to study these processes and identify therapeutic targets.
References
- 1. Sekine Y et al.. 2022. A novel intramolecular negative regulation of mouse Jak3 activity by tyrosine 820.. Int Immunol 34(6):303-312 PMID: 35192696
- 2. Swiatek-Machado K et al.. 2020. STAT Signaling in Glioma Cells.. Adv Exp Med Biol 1202:203-222 PMID: 32034715
- 3. Linossi EM et al.. 2018. Understanding SOCS protein specificity.. Growth Factors 36(3-4):104-117 PMID: 30318950
- 4. Imada K et al.. 2000. The Jak-STAT pathway.. Mol Immunol 37(1-2):1-11 PMID: 10781830
- 5. Keating N et al.. 2025. ARAP2 regulates responses to interferon-gamma by restricting SOCS1.. Cell Rep 44(12):116667 PMID: 41401070
- 6. Greenhalgh CJ et al.. 2001. Negative regulation of cytokine signaling.. J Leukoc Biol 70(3):348-56 PMID: 11527983
- 7. Frankson R et al.. 2017. Therapeutic Targeting of Oncogenic Tyrosine Phosphatases.. Cancer Res 77(21):5701-5705 PMID: 28855209
- 8. Haque SJ et al.. 1998. Protein-tyrosine phosphatase Shp-1 is a negative regulator of IL-4- and IL-13-dependent signal transduction.. J Biol Chem 273(51):33893-6 PMID: 9852037
